Results 221 to 230 of about 1,536,180 (350)

U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab [PDF]

, 2010
Steven J. Lemery, Jenny Zhang, Mark D. Rothmann, Jun Yang, Justin Earp, Hong Zhao, Andrew McDougal, Anne M. Pilaro, Raymond Chiang, Joseph E. Gootenberg, Patricia Keegan, Richard Pazdur   +11 more
openalex   +1 more source

Preparation and characterization of renal cell peptides from fetal rats for their antitumor activity

FEBS Open Bio, EarlyView.
This study aimed to prepare renal cells (RCs) from fetal rats which were digested by enzymes. Candidate peptides RCPs were characterized by capillary HPLC and MS and their bioactivity was predicted using peptideranker. The predicted top 10 bioactive peptides were synthesized.
Zhe Zhang, Yuan Cao, Jing Du, Ying Zhang, Junxia Wang, Ying Yuan, Lianqing Sun   +6 more
wiley   +1 more source

The evolutionary safety of mutagenic drugs should be assessed before drug approval. [PDF]

PLoS Biol
Lobinska G, Tretyachenko V, Dahan O, Nowak MA, Pilpel Y.   +4 more
europepmc   +1 more source

Clinical Trial Design and Drug Approval in Oncology: A Primer for the Advanced Practitioner in Oncology. [PDF]

J Adv Pract Oncol, 2020
Kurtin SE, Taher R.
europepmc   +1 more source

Impact of pharmacometrics on drug approval and labeling decisions: A survey of 42 new drug applications

, 2005
Venkatesh Atul Bhattaram, Brian Booth, Roshni Ramchandani, B. Nhi Beasley, Yaning Wang, Veneeta Tandon, John Duan, Raman Baweja, Patrick Marroum, Ramana Uppoor, Nam Atiqur Rahman, Chandrahas Sahajwalla, J. Robert Powell, Mehul U. Mehta, Jogarao Gobburu   +14 more
openalex   +2 more sources

Federal Advisory Committees, Policy Expertise, and the Approval of Drugs and Medical Devices at the FDA [PDF]

, 2010
Stéphane Lavertu, David L. Weimer
openalex   +1 more source

Phenotypic plasticity in a novel set of EGFR tyrosine kinase inhibitor‐adapted non‐small cell lung cancer cell lines

FEBS Open Bio, EarlyView.
Phenotypic plasticity in a newly established set of EGFR inhibitor‐adapted NSCLC cell lines during adaptation and in established cell lines. Here, we introduce novel sublines of the EGFR‐mutant non‐small cell lung cancer (NSCLC) cell lines HCC827 and HCC4006 adapted to the EGFR kinase inhibitors gefitinib (HCC827rGEFI2μm, HCC4006rGEFI1μm), erlotinib ...
Tharsagini V. Nanthaprakash, Campbell W. Gourlay, Ina Oehme, Michelle D. Garrett, Jindrich Cinatl Jr, Mark N. Wass, Martin Michaelis   +6 more
wiley   +1 more source

Machine Learning with Statistical Imputation for Predicting Drug Approval

Harvard Data Science Review, 2021
Andrew W. Lo, Kien Wei Siah, Chi Heem Wong   +2 more
doaj   +1 more source

Making Drug Approval Decisions in the Face of Uncertainty: Cumulative Evidence versus Value of Information. [PDF]

Med Decis Making
Dijk SW, Krijkamp E, Kunst N, Labrecque JA, Gross CP, Pandit A, Lu CP, Visser LE, Wong JB, Hunink MGM.   +9 more
europepmc   +1 more source

Ro 31‐8220 suppresses bladder cancer progression via enhancing autophagy in vitro and in vivo

FEBS Open Bio, EarlyView.
The pan‐protein kinase C inhibitor Ro‐31‐8220 demonstrates potent anti‐bladder cancer effects both in vitro and in vivo by suppressing migration/invasion, inducing apoptosis and crucially activating autophagy, where blocking autophagy with chloroquine reduces its cell‐killing efficacy, suggesting its promise as a novel therapeutic candidate requiring ...
Shengjun Fu, Yan Tao, Shan Wu, Yuwen Gong, Youli Zhao, Shaomin Niu, Hui Cheng, You Mu, Na Xu, Ying Wang, Jianzhong Lu, Shanhui Liu, Lanlan Li   +12 more
wiley   +1 more source